Rest heart rate and life expectancy

Among mammals, there is an inverse semilogarithmic relation between heart rate and life expectancy. The product of these variables, namely, the number of heart beats/lifetime, should provide a mathematical expression that defines for each species a predetermined number of heart beats in a lifetime. Plots of the calculated number of heart beats/lifetime among mammals against life expectancy and body weight (allometric scale of 0.5 x 10(6)) are, within an order of magnitude, remarkably constant and average 7.3 +/- 5.6 x 10(8) heart beats/lifetime. A study of universal biologic scaling and mortality suggests that the basal energy consumption/body atom per heart beat is the same in all animals (approximately 10(-8) O2 molecules/heart beat). These data yield a mean value of 10 x 10(8) heart beats/lifetime and suggest that life span is predetermined by basic energetics of living cells and that the apparent inverse relation between life span and heart rate reflects an epiphenomenon in which heart rate is a marker of metabolic rate. Thus, the question of whether human life can be extended by cardiac slowing remains moot and most likely will only be resolved by retrospective analyses of large populations, future animal studies and clinical trials using bradycardic therapy.

This article has been cited by other articles:

				H. Nagele, W. Rodiger, and M. A. Castel Rate-responsive pacing in patients with heart failure: long-term results of a randomized study Europace, August 21, 2008; (2008) eun213v1. [Abstract] [Full Text] [PDF]

				J.-C. Tardif The pivotal role of heart rate in clinical practice: from atherosclerosis to acute coronary syndrome Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F11 - F16. [Abstract] [Full Text] [PDF]

				J. C. Russell, S. D. Proctor, S. E. Kelly, and D. N. Brindley Pair feeding-mediated changes in metabolism: stress response and pathophysiology in insulin-resistant, atherosclerosis-prone JCR:LA-cp rats Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1078 - E1087. [Abstract] [Full Text] [PDF]

				R. Kolloch, U. F. Legler, A. Champion, R. M. Cooper-DeHoff, E. Handberg, Q. Zhou, and C. J. Pepine Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) Eur. Heart J., May 2, 2008; 29(10): 1327 - 1334. [Abstract] [Full Text] [PDF]

				M. R. Carnethon, L. Yan, P. Greenland, D. B. Garside, A. R. Dyer, B. Metzger, and M. L. Daviglus Resting Heart Rate in Middle Age and Diabetes Development in Older Age Diabetes Care, February 1, 2008; 31(2): 335 - 339. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]

				W. G. Tingley, L. Pawlikowska, J. G. Zaroff, T. Kim, T. Nguyen, S. G. Young, K. Vranizan, P.-Y. Kwok, M. A. Whooley, and B. R. Conklin Gene-trapped mouse embryonic stem cell-derived cardiac myocytes and human genetics implicate AKAP10 in heart rhythm regulation PNAS, May 15, 2007; 104(20): 8461 - 8466. [Abstract] [Full Text] [PDF]

				S. Cook, M. Togni, M. C. Schaub, P. Wenaweser, and O. M. Hess High heart rate: a cardiovascular risk factor? Eur. Heart J., October 2, 2006; 27(20): 2387 - 2393. [Full Text] [PDF]

				B. Silke Beta-blockade in CHF: pathophysiological considerations Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C13 - C18. [Abstract] [Full Text] [PDF]

				M. Tendera Editorial: If inhibition: from pure heart reduction to treatment of stable angina Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H3 - H6. [Full Text] [PDF]

				R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]

				J. S. Borer Heart rate slowing by If inhibition: therapeutic utility from clinical trials Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]

				A. Diaz, M. G. Bourassa, M.-C. Guertin, and J.-C. Tardif Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease Eur. Heart J., May 2, 2005; 26(10): 967 - 974. [Abstract] [Full Text] [PDF]

				R. Ferrari Editorial: heart rate Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G1 - G2. [PDF]

				R. Ferrari, S. Censi, F. Mastrorilli, and A. Boraso Prognostic benefits of heart rate reduction in cardiovascular disease Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G10 - G14. [Abstract] [PDF]

				S. Yusuf and A. J. Camm Sinus Tachyarrhythmias and the Specific Bradycardic Agents: A Marriage Made in Heaven? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 89 - 105. [Abstract] [PDF]

				N. Singh Diabetes, Heart Rate, and Mortality Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2002; 7(2): 117 - 129. [Abstract] [PDF]

				B. N. Singh Morbidity and Mortality in Cardiovascular Disorders: Impact of Reduced Heart Rate Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 313 - 331. [PDF]

				T Laperche, D Logeart, A Cohen-Solal, and R Gourgon Potential interests of heart rate lowering drugs Heart, April 1, 1999; 81(4): 336 - 341. [Full Text]

				A. Avolio, D. Jones, and M. Tafazzoli-Shadpour Quantification of Alterations in Structure and Function of Elastin in the Arterial Media Hypertension, July 1, 1998; 32(1): 170 - 175. [Abstract] [Full Text] [PDF]